WCLC重磅发布！复宏汉霖PD-L1 ADC HLX43研究结果入选大会口头报告和壁报导览

在本次大会上，复宏汉霖创新型PD-L1 ADC HLX43治疗晚期/转移性实体瘤的临床I期更新数据成功入选口头报告和壁报导览两个环节。在由IASLC、中国临床肿瘤学会（CSCO）和中国肺癌防治联盟（CAALC）共同举办的Joint IASLC-CSCO-CAALC Session联席会议上，HLX43的临床I期更新数据将作为肺癌前沿研究的代表，由牵头主要研究者、中国医学科学院肿瘤医院王洁教授在西班牙时间9月6日上午11:00- 11:06以口头报告的形式进行汇报。同时，该研究数据还将于西班牙时间9月8日下午2:31-2:39，在WCLC大会壁报导览环节进行汇报。摘要数据信息显示，HLX43在晚期实体瘤、尤其是绝大多数接受过检查点抑制剂（CPI）治疗并失败的后线耐药NSCLC患者中，持续表现出高应答率，在特定亚组如EGFR野生型nsNSCLC人群中展现了更为优异的疗效，ORR达47.4%，同时延续了良好的安全性。

此外，复宏汉霖创新型抗EGFR单抗HLX07联合斯鲁利单抗(联合或不联合化疗)用于EGFR高表达sqNSCLC的一线治疗的II期研究也将以壁报形式在本次大会上发布更新数据。公司创新型抗PD-1单抗H药 汉斯状^®三项研究入选大会口头报告，其中H药一线治疗晚期非鳞状非小细胞肺癌III期临床研究（ASTRUM-002）结果将在大会口头首次发布。

复宏汉霖持续深耕肺癌治疗领域，从H药引领小细胞肺癌免疫治疗，到PD-L1 ADC HLX43、抗EGFR单抗HLX07等多元创新管线覆盖更多分子分型，公司将以差异化、全人群覆盖的产品矩阵，不断引领肺癌创新前沿，造福全球更多患者。

Henlius' PD-L1 ADC HLX43 selected for oral presentation and poster tour session at 2025 WCLC!

2025 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer(IASLC)  will be held from September 6-9 in Barcelona, Spain‌. At this year’s WCLC, Henlius will unveil the latest results from 10 studies on its three core innovative products in the field of lung cancer: PD-L1 ADC HLX43, anti-PD-1 monoclonal antibody(mAb) HANSIZHUANG, and anti-EGFR mAb HLX07. These include 4 oral presentations and 2 poster tours, highlighting comprehensive first-line therapies for lung cancer and underscoring Henlius' innovative leadership in advancing lung cancer treatment.

Among the highlights is the updated results of the Phase 1 clinical trial of HLX43, Henlius’ PD-L1 ADC, which secured spots in both the oral presentation and poster tour session. During the Joint IASLC-CSCO-CAALC Session co-hosted by IASLC, the Chinese Society of Clinical Oncology (CSCO), and the China Lung Cancer Prevention and Treatment Alliance (CAALC), HLX43' updated phase 1 resultes will be orally repsented by its leading principal investigator, Professor Wang Jie from the Cancer Hospital of the Chinese Academy of Medical Sciences on September 6(11:00 AM-11:06 AM). The updated data will also be presented in poster tour session at the WCLC on September 8, 2025, from 2:31 to 2:39 PM in Spain. According to the abstract data, HLX43 continues to demonstrate a high response rate in patients with advanced solid tumors, particularly in pretreated NSCLC patients who failed checkpoint inhibitor therapy. HLX43 exhibits superior efficacy in specific subgroups, with an objective response rate (ORR) of 47.4% in EGFR wild-type non-squamous NSCLC, while maintaining a favorable safety profile. 

In addition, the updated results of a Phase 2 study evaluating Henlius' innovative anti-EGFR monoclonal antibody(mAb) HLX07 in combination with serplulimab for first-line treatment of EGFR high expression squamous non-small cell lung cancer (sqNSCLC) will be presented in poster form at this conference. Furthermore, three studies of the company's innovative anti-PD-1 mAb HANSIZHUANG have been selected for oral presentations at the conference, including the Phase III clinical study (ASTRUM-002) for first-line treatment of advanced non-squamous non-small cell lung cancer, which will debut its results in an oral presentation.

Henlius remains dedicated to advancing lung cancer therapies, from HANSIZHUANG leading small cell lung cancer immunotherapy to PD-L1 ADC HLX43, anti-EGFR mAb HLX07, and other diverse innovative pipelines covering more molecular subtypes. With a differentiated product portfolio addressing various patient needs, Henlius strives to remain at the forefront of lung cancer innovation, bringing hope and benefits to patients around the globe.

媒体：PR@Henlius.com

投资者：IR@Henlius.com